Poland· PL-100327330
Xultophy
A insulin degludec and liraglutide product containing insulinum degludecum + liraglutidum, registered in Poland by Novo Nordisk A/S. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Insulin degludec and liraglutide is registered in 12 of 19 countries.
Countries holding a registration under ATC A10AE56 (insulin degludec and liraglutide), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Insulin degludec and liraglutide · ATC A10AE56
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Insulinum degludecum + Liraglutidum
- Manufacturer
- Novo Nordisk A/S
- Country
- Poland (PL)
- ATC code
- A10AE56
- ATC class
- Insulin degludec and liraglutide
- Defined daily dose
- 40 E, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Insulin degludec and liraglutide in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXULTOPHYNovo Nordisk A/S, Bagsvaerd
- NorwayXultophyOrifarm AS
- SpainXULTOPHY 100 U/ML + 3,6 MG/ML SOLUCION INYECTABLENovo Nordisk A/S
- FinlandXultophyNovo Nordisk A/S
- FranceXULTOPHY 100 unités/ml + 3,6 mg/ml, solution injectableNOVO NORDISK (DANEMARK)
- United KingdomXultophy 100units/ml / 3.6mg/ml solution for injection 3ml pre-filled pensNovo Nordisk Ltd
- IrelandXultophy 100 units/mL + 3.6 mg/mL solution for injection.Novo Nordisk A/S
- IcelandXultophyNovo Nordisk A/S*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Xultophy
- Norway · Xultophy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e4a2d007-7fa8-41b9-8284-ca3cfb728f04 GET /v1/drugs/e4a2d007-7fa8-41b9-8284-ca3cfb728f04?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "100 j./ml + 3,6 mg/ml",
"packaging": "Rp ¦ EU/1/14/947/002 ¦ 104782\n3 wstrzykiwacze 3 ml\nRp ¦ EU/1/14/947/004 ¦ 104783\n10 wstrzykiwaczy 3 ml\nRp ¦ EU/1/14/947/003 ¦ 104784\n5 wstrzykiwaczy 3 ml\nRp ¦ EU/1/14/947/001 ¦ 104785\n1 wstrzykiwacz 3 ml",
"substance": "Insulinum degludecum 100 j./1 ml + Liraglutidum 3.6 mg/ml/1 ml",
"common_name": "Insulinum degludecum + Liraglutidum",
"pl_product_id": "100327330",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about insulin degludec and liraglutide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.